Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib OLE in Juvenile Idiopathic Arthritis
NCT07553182Phase 3Recruiting
- Sponsor
- Alfasigma
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of filgotinib in juvenile idiopathic arthritis (JIA), sponsored by Alfasigma. Started Apr 2026; status: recruiting.
02
Drugs
filgotinib
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT07553182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07553182.